Artisan Partners Limited Partnership Trims Position in Icon Plc $ICLR

Artisan Partners Limited Partnership lowered its holdings in Icon Plc (NASDAQ:ICLR) by 1.6% in the third quarter, Holdings Channel.com reports. The firm owned 7,071,360 shares of the medical research company’s stock after selling 113,510 shares during the period. Icon accounts for 1.8% of Artisan Partners Limited Partnership’s investment portfolio, making the stock its 14th largest holding. Artisan Partners Limited Partnership owned approximately 0.09% of Icon worth $1,237,488,000 at the end of the most recent quarter.

Several other institutional investors have also recently added to or reduced their stakes in ICLR. Private Trust Co. NA lifted its position in Icon by 200.0% during the third quarter. Private Trust Co. NA now owns 141 shares of the medical research company’s stock worth $25,000 after buying an additional 94 shares during the period. Wilmington Savings Fund Society FSB increased its stake in shares of Icon by 153.4% during the 3rd quarter. Wilmington Savings Fund Society FSB now owns 332 shares of the medical research company’s stock valued at $58,000 after acquiring an additional 201 shares during the last quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. purchased a new position in shares of Icon during the 2nd quarter worth about $61,000. Pilgrim Partners Asia Pte Ltd acquired a new stake in shares of Icon in the third quarter worth approximately $63,000. Finally, Geneos Wealth Management Inc. boosted its position in shares of Icon by 11.5% in the second quarter. Geneos Wealth Management Inc. now owns 541 shares of the medical research company’s stock worth $79,000 after acquiring an additional 56 shares during the last quarter. 95.61% of the stock is currently owned by institutional investors and hedge funds.

Icon Trading Up 5.1%

NASDAQ ICLR opened at $106.13 on Friday. The stock has a market cap of $8.57 billion, a P/E ratio of 14.36, a PEG ratio of 2.59 and a beta of 1.27. The company’s fifty day simple moving average is $160.76 and its 200-day simple moving average is $170.69. The company has a current ratio of 1.06, a quick ratio of 1.06 and a debt-to-equity ratio of 0.31. Icon Plc has a 52 week low of $66.57 and a 52 week high of $211.00.

Analyst Ratings Changes

ICLR has been the subject of several research analyst reports. Leerink Partners reaffirmed a “market perform” rating and set a $105.00 price target on shares of Icon in a research report on Thursday, February 12th. Mizuho set a $216.00 price objective on shares of Icon in a research note on Friday, January 9th. Jefferies Financial Group set a $135.00 target price on Icon and gave the stock a “buy” rating in a research report on Monday. Rothschild & Co Redburn set a $100.00 target price on Icon and gave the company a “neutral” rating in a report on Tuesday, February 17th. Finally, Truist Financial reissued a “hold” rating and set a $222.00 price target (down from $231.00) on shares of Icon in a research report on Thursday, January 8th. Six investment analysts have rated the stock with a Buy rating, ten have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $157.47.

Icon Company Profile

Icon plc (NASDAQ: ICLR) is a global provider of outsourced drug development and clinical research services to the pharmaceutical, biotechnology and medical device industries. The company partners with clients at all stages of the product life cycle, offering expertise in protocol design, trial execution and regulatory compliance across a broad range of therapeutic areas.

Icon’s service portfolio encompasses clinical trial management, data management and biostatistics, medical imaging, pharmacovigilance and safety monitoring, laboratory sciences and specialized analytical solutions.